Cue Biopharma (CUE) news
Recent news
Cue Biopharma shares reverse premarket gains; last down 3.3%
Cue Biopharma Inc. (NASDAQ: CUEB) shares reversed earlier premarket gains, trading down 3.3% as of 9:30 a.m. ET on September 21, 2026. The stock initially rose in premarket trading following the release of updated data from a Phase 2 clinical trial for its investigational therapy, CUE-101, in…
AInvest Wire · Sep 21, 2026Cue Biopharma shares jump 48.2% premarket after positive results from mid-stage study for Cue-221 in HIVES treatment
Cue Biopharma Inc. (NASDAQ: CUEB) shares rose 48.2% in premarket trading on September 21, 2026, following the release of positive mid-stage clinical trial results for its investigational therapy, Cue-221, in the treatment of HIVES [1]. The Phase II trial demonstrated statistically significant…
AInvest Wire · Sep 21, 2026Cue Biopharma, - Phase 2 primary and key secondary endpoints met
AInvest Wire · Sep 20, 2026Cue Biopharma announces positive topline results from Cue-221 phase 2 study in chronic spontaneous urticaria
AInvest Wire · Sep 20, 2026Cue Biopharma, Inc.: B. Riley initiates coverage with buy rating; target price $83
B. Riley Financial has initiated coverage on Cue Biopharma (NASDAQ: CUE) with a "Buy" rating and an $83 price target, representing potential 119.34% upside from the stock’s current price of $37.84. This recommendation comes amid a mixed analyst landscape, with two other analysts assigning a "Buy"…
AInvest Wire · Sep 18, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.